C4X Discovery’s (L:C4XD) proprietary drug discovery platform allows the accurate measurement of molecular shapes in solution enabling improved and accelerated drug discovery. It has five programmes targeting validated clinical targets, with plans to add substantially to these in the next couple of years. The Orexin programme’s lead candidate, a selective OX1 antagonist, is in formal preclinical studies with clinical development anticipated by mid-2017. We suggest that the potential of this programme alone largely supports the current valuation, indicating that significant potential upside value is not yet ascribed.
To read the entire report Please click on the pdf File Below